Philip Frost

10.6k citations

121 papers · 8.2k indexed · 5 hit papers · h-index 42

Molecular Biology top 2%
Oncology top 0.5%
Genetics top 1%
Cancer Research top 1%
Pathology and Forensic Medicine top 0.5%

Co-authors: Bert Vogelstein David Sidransky Robert S. Kerbel Stanley R. Hamilton Ellis D. Avner William E. Sweeney Kenneth W. Kinzler James J. Gibbons
Topics: Cancer Genomics and Diagnostics (23 papers)Immunotherapy and Immune Responses (15 papers)Cancer Research and Treatments (12 papers)
Cited by: Oncology Cancer Research Pathology and Forensic Medicine
Journals: Nature Science New England Journal of Medicine
Partner nations: United States Canada South Africa

In The Last Decade

Philip Frost

121 papers receiving 7.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR

2001 806 citations Philip Frost et al. profile →
Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

1990 769 citations Eric R. Fearon, Philip Frost et al. profile →
Identification of p53 Gene Mutations in Bladder Cancers and Urine Samples

1991 731 citations Philip Frost et al. profile →
Identification of ras Oncogene Mutations in the Stool of Patients with Curable Colorectal Tumors

1992 555 citations Philip Frost et al. profile →
Clonal Origin of Bladder Cancer

1992 428 citations Philip Frost et al. profile →

Peers

Countries citing papers authored by Philip Frost

Since Specialization

Citations

This map shows the geographic impact of Philip Frost's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Frost with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Frost more than expected).

Fields of papers citing papers by Philip Frost

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Frost. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Frost. The network helps show where Philip Frost may publish in the future.

Co-authorship network of co-authors of Philip Frost

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Frost. A scholar is included among the top collaborators of Philip Frost based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Frost. Philip Frost is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease 2017 ·World Journal of Nephrology ·William E. Sweeney,Philip Frost,Ellis D. Avner	46
2	Neuroprotective Profile of Novel Src Kinase Inhibitors in Rodent Models of Cerebral Ischemia 2009 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown),Kevin Pong,Cathleen Gonzales,Yi Chen,Huai‐Ping Ling,Robert J. Mark,Frank Boschelli,Diane H. Boschelli,Fei Ye,Ana Carolina Barrios Sosa,Tarek S. Mansour,Philip Frost,Andrew Wood,Menelas N. Pangalos,Margaret M. Zaleska	32
3	Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus 2006 ·Endocrine Related Cancer ·(unknown),(unknown),Tami Annable,Philip Frost,Lee M. Greenberger,Yixian Zhang	30
4	Identification and Characterization of 4-[[4-(2-Butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3 S)thiomorpholinecarboxamide (TMI-1), a Novel Dual Tumor Necrosis Factor-α-Converting Enzyme/Matrix Metalloprotease Inhibitor for the Treatment of Rheumatoid Arthritis 2004 ·Journal of Pharmacology and Experimental Therapeutics ·Yuhua Zhang,Jun Xu,Jeremy I. Levin,Martin Hegen,Guangde Li,Heidi Robertshaw,Fionula M. Brennan,Terri Cummons,(unknown),Nichole R. Vansell,Cheryl Nickerson‐Nutter,D. Barone,K M Mohler,Roy A. Black,J.S. Skotnicki,Jay Gibbons,Marc Feldmann,Philip Frost,G R Larsen,Lih‐Ling Lin	74
5	Development and comparison of two nonradioactive kinase assays for I kappa B kinase 2004 ·Analytical Biochemistry ·Tammy Sadler,(unknown),(unknown),(unknown),James LaRocque,J. M. JUN. MORIN,(unknown),Lee M. Greenberger,Philip Frost,Yixian Zhang	17
6	Flooding Patterns of the Okavango Wetland in Botswana between 1972 and 2000 2003 ·AMBIO ·Jenny McCarthy,Thomas Gumbricht,T.S. McCarthy,Philip Frost,Konrad Wessels,Frank Seidel	11
7	Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability 2003 ·Kidney International ·William E. Sweeney,Kiyoshi Hamahira,Jennifer Sweeney,(unknown),Philip Frost,Ellis D. Avner	66
8	Remote sensing to detect sub-surface peat fires and peat fire scars in the Okavango Delta, Botswana : research article 2002 ·South African Journal of Science ·Thomas Gumbricht,T.S. McCarthy,Jenny McCarthy,David P. Roy,Philip Frost,Konrad Wessels	15
9	A novel inhibitor of tumor necrosis factor-α converting enzyme ameliorates polycystic kidney disease 2001 ·Kidney International ·(unknown),(unknown),William E. Sweeney,Jeremy I. Levin,Philip Frost,Ellis D. Avner	53
10	Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor 2000 ·Kidney International ·William E. Sweeney,Yue-Gang Chen,Koichi Nakanishi,Philip Frost,Ellis D. Avner	174
11	2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation 1993 ·British Journal of Cancer ·(unknown),Philip Frost,(unknown),RA Newman,Yuti Chernajovsky	16
12	Clinical implications of metastatic process 1992 ·The Lancet ·Philip Frost,B. Levin	48
13	Unknown Primary Tumors: An Example of Accelerated (Type 2) Tumor Progression 1991 ·PubMed ·Philip Frost	10
14	Cytogenetic heterogeneity of genetically marked and metastatically competent “dominant” tumor cell clones 1991 ·Cancer Genetics and Cytogenetics ·(unknown),Philip Frost,Robert S. Kerbel	16
15	Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid 1990 ·Cancer Chemotherapy and Pharmacology ·James L. Abbruzzese,Robert J. Amato,(unknown),Martin N. Raber,Philip Frost	4
16	Genotypic and Phenotypic Evidence of Clonal Interactions in Murine Tumor Cells 1989 ·JNCI Journal of the National Cancer Institute ·Toshiyuki Itaya,Jean‐Gabriel Judde,(unknown),Philip Frost	14
17	Systemic immunity against a murine colon tumor (CT‐26) produced by immunization with syngeneic cells expressing a transfected viral gene product 1989 ·International Journal of Cancer ·Hans K. Schackert,Toshiyuki Itaya,Gabriele Schackert,Eric R. Fearon,Bert Vogelstein,Philip Frost	13
18	Pitfalls and practice of Luria-Delbrück fluctuation analysis: a review. 1988 ·PubMed ·Wayne S. Kendal,Philip Frost	80
19	Immunology of prostatic carcinoma-an overview. 1976 ·PubMed ·Philip Frost,Noel R. Rose,(unknown)	3
20	Further evidence for the role of macrophages in the initiation of lymphocyte trapping. 1974 ·The Mouseion at the JAXlibrary (Jackson Laboratory) ·Philip Frost	19

About Philip Frost

Philip Frost is a scholar working on Cancer Research, Oncology and Biotechnology, having authored 121 papers that have together received 8.2k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (23 papers), Immunotherapy and Immune Responses (15 papers) and Cancer Research and Treatments (12 papers). The work is most often cited by research in Oncology (3.0k citations), Cancer Research (1.4k citations) and Pathology and Forensic Medicine (1.4k citations). Philip Frost has collaborated with scholars based in United States, Canada and South Africa. Frequent co-authors include Bert Vogelstein, David Sidransky, Robert S. Kerbel, Stanley R. Hamilton, Ellis D. Avner, William E. Sweeney, Kenneth W. Kinzler, James J. Gibbons, Eric R. Fearon and Carolyn Discafani. Their work appears in journals such as Nature, Science and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact